文献速递肝病消化道肿瘤与早癌

肝移植等待名单上肝细胞癌肿瘤大小报告的偏倚

Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list.
PubMed 文献 · Hepatology · 2017-08-26

研究利用美国器官共享联合网络/标准移植分析与研究数据库,分析2006至2013年12,958例因肝细胞癌获得例外点的肝移植等待者,其中9,168例为单发肿瘤。拟合直方图发现2.0 cm和5.0 cm处观察计数分别超出预期238例(22%)和66例(57%),提示最多304例(3.0%)不符合移植标准的肿瘤被记录在资格边缘。仅2.0 cm肿瘤的复发观察/预期比为0.73(95%CI 0.57-0.94),低于预期27%。

要点

  • 移植标准下限(2.0 cm)和上限(5.0 cm)附近观察到的肿瘤计数高于拟合预期。
  • 2.0 cm和5.0 cm处观察与预期计数差分别为238例(22%)和66(57%)。
  • 仅2.0 cm肿瘤的肝细胞癌复发观察/预期比为0.73(95%CI 0.57-0.94),低于预期27%。

核心结论

  • 移植标准边缘的肿瘤计数高于预期,且2.0 cm肿瘤复发率低于预期,提示边缘肿瘤大小可能存在不准确报告。

研究设计与样本

  • 基于美国器官共享联合网络/标准移植分析与研究数据库,纳入2006至2013年因肝细胞癌获得例外点的肝移植等待者12,958例,其中9,168例为单发肿瘤。
  • 对单发肿瘤大小直方图拟合逻辑斯蒂幂峰函数,以拟合值代表无偏预期值。
  • 采用风险调整泊松模型评估按肿瘤大小的肝细胞癌复发观察/预期比。

主要发现

  • 2.0 cm处观察与预期肿瘤计数差为238例(22%),5.0 cm处为66例(57%)。
  • 提示最多304例(3.0%)不符合移植标准的肿瘤其测量值被记录在资格边缘。
  • 6,049例移植中发生435例肝细胞癌复发;仅2.0 cm肿瘤的复发观察/预期比异于1(比值0.73,95%CI 0.57-0.94),即复发率低于预期27%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We investigated the possibility that patients with hepatocellular carcinoma (HCC) listed for liver transplant with tumors just outside stage T2 size criteria may be inaccurately reported as just meeting the tumor size criteria for transplant. The United Network for Organ Sharing/Standard Transplant Analysis and Research database identified 12,958 patients listed for liver transplants with HCC exception points from 2006 to 2013, 9,168 of whom were listed with one tumor. A logistic power peak function was fitted to the single-tumor size histogram, with the fitted values representing unbiased expected values. The difference between the observed and expected tumor counts for 2.0 cm and 5.0 cm was 238 (22%) and 66 (57%), respectively. This suggests that up to 304 (3.0%) patients with tumors outside of transplant criteria had their measurements recorded at the margins of eligibility. A risk-adjusted Poisson model evaluated the ratio of observed to expected HCC recurrence by tumor size. There were 435 HCC recurrences among 6,049 transplants. Only 2.0-cm tumors had observed to expected recurrence differing from 1 (ratio 0.73, 95% confidence interval 0.57-0.94), indicating a 27% lower than expected rate of recurrence. CONCLUSION: Higher than expected observed tumor counts at the lower transplant criteria margin were corroborated by lower than expected HCC recurrence, suggesting that tumor sizes at the margins of HCC transplant criteria may be subject to inaccurate reporting. (Hepatology 2017;66:1144-1150).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Samoylova ML, Nigrini MJ, Dodge JL, et al. Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list. Hepatology. 2017. PMID: 28520210. doi:10.1002/hep.29269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。